Last reviewed · How we verify
SOF+RBV
SOF+RBV is a combination of sofosbuvir (a nucleotide polymerase inhibitor) and ribavirin (a nucleoside analog) that inhibits hepatitis C virus replication.
SOF+RBV is a combination of sofosbuvir (a nucleotide polymerase inhibitor) and ribavirin (a nucleoside analog) that inhibits hepatitis C virus replication. Used for Chronic hepatitis C virus infection (genotype-dependent, primarily genotypes 2 and 3).
At a glance
| Generic name | SOF+RBV |
|---|---|
| Also known as | GS-7977, PSI-7977, Sovaldi®, Copegus® |
| Sponsor | Humanity and Health Research Centre |
| Drug class | Direct-acting antiviral (DAA) combination |
| Target | HCV NS5B RNA polymerase; viral replication machinery |
| Modality | Small molecule |
| Therapeutic area | Virology / Hepatology |
| Phase | FDA-approved |
Mechanism of action
Sofosbuvir inhibits the NS5B RNA-dependent RNA polymerase of hepatitis C virus, blocking viral RNA synthesis. Ribavirin is a broad-spectrum antiviral nucleoside analog that interferes with viral replication and enhances immune response. Together, they provide direct-acting antiviral activity against HCV.
Approved indications
- Chronic hepatitis C virus infection (genotype-dependent, primarily genotypes 2 and 3)
Common side effects
- Fatigue
- Headache
- Anemia
- Nausea
- Insomnia
Key clinical trials
- Switching Regimen in Treating Cirrhotic HCV GT1b Subjects (PHASE2)
- Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021) (PHASE2)
- A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection
- Safety and Efficacy of Sofosbuvir-Based Regimens in the Treatment of Egyptian Patients With Hepatitis C Infection (PHASE4)
- Combined Ribavirin With Sofosbuvir/Velpatasvir/Voxilaprevir in Retreatment of Chronic Hepatitis C Non-responders (PHASE4)
- Efficacy and Safety of SOF/VEL + RBV and SOF/VEL/VOX for 12 Weeks in HCV Subjects With GT3b and Compensated Cirrhosis (PHASE4)
- Re-treatment of HCV Following DAA Failure (NA)
- Efficacy and Safety of Glecaprevir (ABT-493)/Pibrentasvir (ABT 530) (GLE/PIB) in Combination With Sofosbuvir and Ribavirin in Participants With Hepatitis C Virus Who Did Not Respond to Treatment in a Previous AbbVie Clinical Study (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SOF+RBV CI brief — competitive landscape report
- SOF+RBV updates RSS · CI watch RSS
- Humanity and Health Research Centre portfolio CI